Medication during robotic thyroid cancer surgery
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether adding a targeted medication (mitoxantrone hydrochloride) during robotic thyroid surgery helps treat thyroid cancer more effectively, while also aiming to reduce side effects. The goal is to improve surgical outcomes and quality of life for patients with early-stage thyroid cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have thyroid cancer (or it is highly suspected) with a tumor smaller than 4 cm, and you are scheduled for surgery to remove all or part of your thyroid gland
- You are generally healthy enough for surgery, based on routine check-ups
- You are willing and able to attend follow-up visits and give written consent
- You do not have serious health problems like heart, liver, kidney, or blood disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the timing of a carbon nanoparticle injection during thyroid cancer surgery improves outcomes. It may help patients who need their whole thyroid removed and have cancer in both lobes or spread to lymph nodes.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This study compares a robotic surgery method using small incisions under the armpit with standard open surgery for papillary thyroid cancer that has spread to lymph nodes on one side of the neck. It aims to see which approach is better for removing cancer and recovery.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
Hear when a new Papillary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.